SLC35G3

Across TCGA pan-cancer cohorts, SLC35G3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC35G3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC35G3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC35G3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

BLCA, UCEC, and LUSC are the cancer types where SLC35G3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.142	0.618	<.001	45	view →
UCEC	DFS	Median	All	1.000	0.619	.006	32	view →
LUSC	OS	Median	II,III,IV	0.203	0.618	.007	17	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.141	0.677	.002	6	view →
LIHC	OS	Median	II,III,IV	0.176	0.617	.019	6	view →
LGG	OS	Median	All	0.294	0.799	.005	3	view →
GBM	DFS	Median	All	1.000	0.204	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC35G3–BLCA (DFS)

Open the BLCA breakdown →